Femur Reconstruction Interlocking Nail System, Femur Retrograde Interlocking Nail System, Humerus Interlocking Nail System, Tibia Interlocking Nail System, Compression Hip Nail System

K230071 · Tdm Co., Ltd. · HSB · Aug 22, 2024 · Orthopedic

Device Facts

• Record ID: K230071
• Device Name: Femur Reconstruction Interlocking Nail System, Femur Retrograde Interlocking Nail System, Humerus Interlocking Nail System, Tibia Interlocking Nail System, Compression Hip Nail System
• Applicant: Tdm Co., Ltd.
• Product Code: HSB · Orthopedic
• Decision Date: Aug 22, 2024
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3020
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Femur Reconstruction Interlocking Nail System is intended to stabilize femoral shaft fractures, subtrochanteric fractures, ipsilateral neck/shaft fractures, impending pathologic fractures, non-unions and malunions. The Femur Retrograde Interlocking Nail System is indicated for simple long bone fractures: severely comminuted, spiral, large oblique and segmental fractures; nonunions; polytrauma and multiple fractures; prophylactic nailing of impending pathologic fractures; reconstruction, following tumor resection and grating; supracondylar fractures; bone lengthening and shortening. Interlocking intramedullary nails are indicated for fixation of fractures that occur in and between the proximal and distal third of long bones being treated. The Humerus Interlocking Nail System indicated for fractures of the proximal humerus, including 2-part surgical neck fractures, 3-part fractures, and 4-part fractures with diaphyseal extension, diaphyseal extension, diaphyseal fractures of the humeral shaft, and impending pathologic humeral fractures. The Tibia Interlocking Nail System is intended to stabilize fractures of the proximal and distal thatt; open and closed tibial shaft fractures; certain pre- and post-isthmic fractures; and tibial malunions and non- unions. The Compression Hip Nail System is intended to treat stable proximal femoral fracture including Pertrochanteric fractures, Intertrochanteric fractures and High sub trochanteric fractures and combination of these fractures.

Device Story

Intramedullary fixation system for stabilization of humeral, femoral, and tibial fractures; consists of various interlocking nails, lag screws, and supplemental screws. Device implanted into medullary cavity of long bones; fracture stabilized by locking screws at proximal and distal ends. Used in clinical/surgical settings by orthopedic surgeons. Provides mechanical fixation to facilitate bone healing and alignment. Benefits include stabilization of complex fractures, non-unions, and pathologic fractures.

Clinical Evidence

No clinical data. Substantial equivalence supported by bench testing including biocompatibility (ISO 10993 series: genotoxicity, cytotoxicity, implantation, sensitization, reactivity, systemic/subchronic toxicity, pyrogens) and mechanical testing (ASTM F1264, ASTM F543, ASTM F384).

Technological Characteristics

Intramedullary fixation rod system; materials: titanium alloy; components: nails, lag screws, supplemental screws; dimensions: similar range to predicate; sterilization: not specified; connectivity: none; software: none; mechanical fixation principle.

Indications for Use

Indicated for patients with long bone fractures (femur, humerus, tibia) including shaft, subtrochanteric, supracondylar, proximal, distal, comminuted, spiral, oblique, segmental, and open/closed fractures; non-unions; malunions; polytrauma; impending pathologic fractures; and tumor resection reconstruction. Compression Hip Nail indicated for stable/unstable proximal femoral fractures (Pertrochanteric, Intertrochanteric, high subtrochanteric).

Regulatory Classification

Identification

An intramedullary fixation rod is a device intended to be implanted that consists of a rod made of alloys such as cobalt-chromium-molybdenum and stainless steel. It is inserted into the medullary (bone marrow) canal of long bones for the fixation of fractures.

Predicate Devices

• Auxein Nailing System (K192003)

Reference Devices

• Synthes Multiloc Humeral Nailing System (K120807)
• Synthes(USA) Tibial Nail System EX (K040762)
• Gamma3 System Lag Screws (K200869)
• T2 Femur Nail (K200880)

Submission Summary (Full Text)

{0}------------------------------------------------

August 22, 2024

Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo includes the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.

Tdm Co., Ltd. % Dave Kim Medical Regulatory Affairs Mtech Group 7505 Fannin St. Suite 610 Houston, Texas 77054

Re: K230071

Trade/Device Name: Femur Reconstruction Interlocking Nail System, Femur Retrograde Interlocking Nail System. Humerus Interlocking Nail System. Tibia Interlocking Nail System. Compression Hip Nail System

Regulation Number: 21 CFR 888.3020 Regulation Name: Intramedullary fixation rod Regulatory Class: Class II Product Code: HSB Dated: August 15, 2024 Received: August 15, 2024

Dear Dave Kim:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"

{1}------------------------------------------------

(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

| Farzana Sharmin -S | Digitally signed by Farzana Sharmin -S<br>Date: 2024.08.22 14:16:28 -04'00' |
|--------------------|-----------------------------------------------------------------------------|
|--------------------|-----------------------------------------------------------------------------|

Farzana Sharmin, PhD Assistant Director DHT6A: Division of Joint Arthroplasty Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

{2}------------------------------------------------

## Indications for Use

510(k) Number (if known) K230071

#### Device Name

Femur Reconstruction Interlocking Nail System. Femur Retrograde Interlocking Nail System, Nail System, Tibia Interlocking Nail System, Compression Hip Nail System

### Indications for Use (Describe)

### (1) Femur Reconstruction Interlocking Nail System

The Femur Reconstruction Interlocking Nail System is intended to stabilize femoral shaft fractures, subtrochanteric fractures, ipsilateral neck/shaft fractures, impending pathologic fractures, non-unions and malunions.

### (2) Femur Retrograde Interlocking Nail System

The Femur Retrograde Interlocking Nail System is indicated for simple long bone fractures: severely comminuted, spiral, large oblique and segmental fractures; nonunions; polytrauma and multiple fractures; prophylactic nailing of impending pathologic fractures; reconstruction, following tumor resection and grating; supracondylar fractures; bone lengthening and shortening. Interlocking intramedullary nails are indicated for fixation of fractures that occur in and between the proximal and distal third of long bones being treated.

### (3) Humerus Interlocking Nail System

The Humerus Interlocking Nail System indicated for fractures of the proximal humerus, including 2-part surgical neck fractures, 3-part fractures, and 4-part fractures with diaphyseal extension, diaphyseal extension, diaphyseal fractures of the humeral shaft, and impending pathologic humeral fractures.

### (4) Tibia Interlocking Nail System

The Tibia Interlocking Nail System is intended to stabilize fractures of the proximal and distal thatt; open and closed tibial shaft fractures; certain pre- and post-isthmic fractures; and tibial malunions and non- unions.

### (5) Compression Hip Nail System

The Compression Hip Nail System is intended to treat stable proximal femoral fracture including Pertrochanteric fractures, Intertrochanteric fractures and High sub trochanteric fractures and combination of these fractures.

Type of Use (Select one or both, as applicable)

X Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

# 510(k) Summary K230071

The following 510(k) summary is being submitted as required by 21 CFR Part 807.92;

| 5.1 | Submitter: | TDM CO., LTD.<br>69, Cheomdan Venture So-Ro 37beon-Gil<br>Gwangju, KR 61003<br>Tel: [phone]<br>Establishment registration number: 3014257776 |
|-----|---------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Contact Person:<br>(Official Correspondent) | Mr. Dave Kim<br>7505 Fannin St. Suite 610, Houston, TX 77054<br>Tel: [phone]<br>Email: [e-mail] |
| | Date Prepared: | 01/25/2024 |
| 5.2 | Device Identification | |
| | Device Trade Name | Femur Reconstruction Interlocking Nail System, Femu<br>Retrograde Interlocking Nail System, Humerus Interlocking<br>Nail System, Tibia Interlocking Nail System, Compression<br>Hip Nail System |
| | Common Name | Intramedullary Fixation Nailing System |
| | Classification Name<br>(Regulation Number) | Intramedullary Fixation Rod<br>(21 CFR 888.3020) |
| | Device Classification | II |
| | Product Code | HSB |

#### 5.3 Predicate and Reference devices:

Predicate device: K192003, "Auxein Nailing System", manufactured by "Auxein Medical Private Limited" Reference device #01: K120807, "Synthes Multiloc Humeral Nailing System", manufactured by "Synthes"

Reference device #02: K040762, "Synthes(USA) Tibial Nail System EX", manufactured by "Synthes" Reference device #03: K200869, "Gamma3 System Lag Screws", manufactured by "Stryker

Trauma GmbH"

Reference device #04: K200880, "T2 Femur Nail", manufactured by "Stryker GmbH"

#### 5.4 Device Description

This intramedullary fixation rod is used for stabilization of shaft fracture in humeral bone, femoral bone and tibial bone. It is implanted into medullary cavity inside of the long bone (humeral bone, femoral bone and tibial bone) with a fracture and the fractured long bone (humeral bone, femoral bone and tibial bone) is fixed to the nail by using the locking screw at the upper and lower parts of the fractured part.

{4}------------------------------------------------

The nailing system consists of the Femur Reconstruction Interlock Nail System, Femur Retrograde Interlocking Nail System, Humerus Interlocking Nail System, Tibia Interlocking Nail System, and Compression Hip Nailing System.

#### . Indications for use

- Femur Reconstruction Interlocking Nail System ●
The Femur Reconstruction Interlocking Nail System is intended to stabilize femoral shaft fractures, subtrochanteric fractures, ipsilateral neck/shaft fractures, impending pathologic fractures, non-unions and malunions.

- . Femur Retrograde Interlocking Nail System
The Femur Retrograde Interlocking Nail System is indicated for simple long bone fractures; severely comminuted, spiral, large oblique and segmental fractures; nonunions and malunions; polytrauma and multiple fractures; prophylactic nailing of impending pathologic fractures; reconstruction, following tumor resection and grafting; supracondylar fractures; bone lengthening and shortening. Interlocking intramedullary nails are indicated for fixation of fractures that occur in and between the proximal and distal third of long bones being treated.

- Humerus Interlocking Nail System .
The Humerus Interlocking Nail System indicated for fractures of the proximal humerus, including 2-part surgical neck fractures, 3-part fractures, and 4-part fractures, proximal humeral fractures with diaphyseal extension, diaphyseal fractures of the humeral shaft, and impending pathologic humeral fractures.

. Tibia Interlocking Nail System The Tibia Interlocking Nail System is intended to stabilize fractures of the proximal and distal tibia and the tibial shaft; open and closed tibial shaft fractures; certain pre- and post-isthmic fractures; and tibial malunions and non- unions.

. Compression Hip Nail System

The Compression Hip Nail System is intended to treat stable and unstable proximal femoral fracture including Pertrochanteric fractures, Intertrochanteric fractures and High sub trochanteric fractures and combination of these fractures.

#### ● Non-clinical Test Conclusion

The following properties were tested based on the referenced standards. All the test results support substantial equivalence to the predicate devices.

- = ISO 10993-3- Genotocixity (Bacterial reverse mutation) & Genotocixity (chromosomal aberration)

{5}------------------------------------------------

- ISO 10993-5- Cytotoxicity
- ISO 10993-6- Implantation
- = ISO 10993-10 Skin Sensitization & Intracutatneous Reactivity
- = ISO 10993-11 Acute systemic toxicity & Subchronic Toxicity & Pyrogens
- = testing per ASTM F1264, ASTM F543, and ASTM F384

#### ● Clinical Test Conclusion

Clinical testing was not required for this submission.

#### Technical Characteristics and Substantial Equivalence ●

The subject device is substantially equivalent to "Auxein Nailing System (K192003)", the predicate device, based on the following:

- . The subject device does not have a new intended use. It shows equivalent specifications with the predicate device in most of the parameters.
- The subject device is intramedullary fixation nailing system which employs Femur Reconstruction ● Interlocking Nail, Femur Retrograde Interlocking Nail System Humerus Interlocking Nail Tibia Interlocking Nail System, and Compression Hip Nail System, designed similar to the predicate device.
- . Both the subject device and the predicate device are made of titanium alloy.
- The nails, lag screws and supplemental screws are in the similar range of lengths and diameters as the predicate device.

## 6. Conclusion:

Based on the testing results, TDM CO., LTD. concludes that the subject devices are substantially equivalent to the predicate device.